• Archana Mukherjee, Haladhar Dev Sarma, Sanjay Saxena, Yogendra Kumar, Pradip Chaudhari, Jayant Sastri Goda, Pranjal Adurkar, Ashutosh Dash, and Grace Samuel.
• Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India.
• Indian J Med Res. 2014 Apr 1; 139 (4): 555-60.

Background & ObjectivesIn recent years, brachytherapy involving permanent radioactive seed implantation has emerged as an effective modality for the management of cancer of prostate. 125 I-Ocu-Prosta seeds were indigenously developed and studies were carried out to assess the safety of the indigenously developed 125 I-Ocu-Prosta seeds for treatment of prostate cancer.MethodsAnimal experiments were performed to assess the likelihood of in vivo release of 125 I from radioactive seeds and migration of seeds implanted in the prostate gland of the rabbit. In vivo release of 125 I activity was monitored by serial blood sampling from the auricular vein and subsequent measurement of 125 I activity. Serial computed tomography (CT) scans were done at regular intervals till 6 months post implant to assess the physical migration of the seeds.ResultsThe laser welded seeds maintained their hermeticity and prevented the in vivo release of 125 I activity into the blood as no radioactivity was detected during follow up blood measurements. Our study showed that the miniature 125 I seeds were clearly resolved in CT images. Seeds remained within the prostate gland during the entire study period. Moreover, the seed displacement was minimal even within the prostate gland.Interpretation & ConclusionsOur findings have demonstrated that indigenously developed 125 I-Ocu-Prosta seeds may be suitable for application in treatment of prostate cancer.

14 keywords...

hide…